This site is intended for healthcare professionals
Light micrograph of a human liver stained with hematoxylin and eosin. The hepatocytes are arranged in cords separated by clear areas where hepatic sinusoids showing red blood cells are located.
Alpha-1 Antitrypsin Deficiency: Bridging Care

AATD liver care: EASL 2025 summary

Last updated: 22nd Oct 2025
Published: 22nd Oct 2025

Key takeaways from the EASL 2025 symposium on AATD

This infographic summarizes the main topics discussed during a symposium chaired by Rohit Loomba, focused on the liver care journey in alpha-1 antitrypsin deficiency (AATD). Whether you attended the session or are catching up, this overview shares key updates on detection, care pathways, and emerging therapies.

Infographic summarizing the EASL 2025 symposium on the liver care journey in alpha-1 antitrypsin deficiency (AATD). Highlights include genotype risk (especially Pi*ZZ, which carries the highest risk of fibrosis, cirrhosis, and hepatocellular carcinoma), early detection, annual screening, and the value of joint liver–lung clinics. Multidisciplinary care and family screening are emphasized, alongside emerging therapies such as CRISPR-based gene editing, siRNA, RNA editing, and folding correctors.

Clinical highlights:

  • Early detection and family screening
    • AATD often presents asymptomatically until advanced liver disease. Early genotype-based screening (especially Pi*ZZ) is critical for identifying high-risk individuals and initiating timely interventions
  • Multidisciplinary liver–lung care
    • Joint clinics and collaborative care between hepatologists and pulmonologists improve outcomes. Annual assessments using FibroScan and spirometry are recommended
  • Non-invasive fibrosis assessment
    • Tools like APRI (aspartate aminotransferase to platelet ratio index) and transient elastography support risk stratification without biopsy
  • Emerging therapies
    • siRNA: Phase 3 trials show promise in reducing liver globule burden
    • RNA editing: Reversible transcript-level therapy in early-phase trials
    • CRISPR gene correction: Preclinical studies targeting misfolded protein pathways
    • Folding correctors: Aim to restore protein secretion and reduce endoplasmic reticulum stress
We should definitely try and work together better so that we can be offering a patient-centered service.
Alice Turner, MBChB
Welcome:

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.